The Rebate Rule: US Pricing Proposal Becomes Congressional Piggy Bank
A policy eliminating rebates in the Medicare Part D program will be delayed until Jan. 1, 2026 – and is very likely to be repealed altogether. If that staves off more draconian reforms, the biopharma industry will celebrate.
You may also be interested in...
For biopharma manufacturers, chipping away at the rebate rule is a relatively painless drug pricing “pay for” compared to price control policies.
US health department’s Office of Inspector General reviews its concerns with allowing remuneration from drug firms in value-based arrangements in latest report to Congress.
Annual Business Group on Health survey on employer-sponsored insurance covers pricing reform, rebate model alternatives, paying for high-cost drugs and copay coupons.